Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: September 2021
Principal Executive Office: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
This filing incorporates by reference the company's Appendix 4E and Annual Report 2021 (Exhibit 99.1) into various Registration Statements on Forms S-8 and F-3.
Key Financial Metrics
The provided filing text serves as a cover sheet and does not contain specific financial data. Consequently, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Investors must refer to the attached Exhibit 99.1 (Appendix 4E & Annual Report 2021) for detailed financial statements.
Material Changes
The filing text does not provide specific details regarding material changes versus prior periods. It indicates the submission of the 2021 Annual Report, which would contain comparative financial data, but the text of the report itself is not included in this input.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. The company is identified as a "development stage enterprise," implying a focus on research and development rather than commercial revenue generation, but specific operational updates are absent from this cover document.
Investor Verification Checklist
- Verify the contents of Exhibit 99.1 (Appendix 4E & Annual Report 2021) for actual financial performance and cash position.
- Confirm the status of the referenced Registration Statements (Forms S-8 and F-3) to understand capital raising activities.
- Review the full Annual Report for details on the company's development stage pipeline and burn rate.